An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
LAVAL, Quebec--(BUSINESS WIRE)--
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in a panel at the Cowen & Co. 42nd Annual Health Care Conference.
Panel Details:
Event: Cowen & Co. 42nd Annual Health Care Conference Title:Respiratory/Infections Panel Date/Time: Tuesday, March 8th, 2022 at 2:10 p.m. ET
A webcast of the panel discussion may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast will be available on the Company’s website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other cough hypersensitivity indications. The Company's product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC. BELLUS is planning a Phase 3 program, which is expected to begin in the second half of 2022.
RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and treatment options are limited.
The Company is exploring the potential use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
bellus health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need. its lead project is blu-5937, a drug candidate for the treatment of chronic cough. bellus health also has economic interests in other partnered drug development projects. blu-5937 is a potent, highly selective, orally bioavailable small molecule antagonist of the p2x3 receptor, a clinically validated target for chronic cough. blu-5937 is a promising best-in-class drug candidate that has the potential to help millions of chronic cough patients who do not respond to current therapies. rights to blu-5937 were obtained under a license agreement with the neomed institute in february 2017. chronic cough is a cough that lasts more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on quality of life. it is estimated that, in the united states alone, more than 2.7 million patients suffer from chronic cough that is
